Appointments of Chief Development and Product Officer and Chief Marketing and Communications Officer
Oxford Nanopore today announces the appointment of David Miller as Chief Development and Product Officer (CDPO) and Conor McKechnie as Chief Marketing and Communications Officer (CMCO), joining on 1st September and 1st October respectively.
Together, these appointments strengthen the Oxford Nanopore’s leadership team, bringing greater alignment between product development, market positioning and commercial execution.
As CDPO, David will lead Product Management, Development and Applications, strengthening the connection between the Company’s strategy, development priorities and product portfolio.
David joins Oxford Nanopore from Pacific Biosciences, where he served as Head of Research & Development and Vice President, Global Marketing. Prior to that, he held senior product leadership roles at Illumina, including responsibility for major platform launches.
As CMCO, Conor will lead Oxford Nanopore’s global Marketing and Corporate Affairs functions, with responsibility for strengthening market positioning, customer engagement and the Company’s corporate and technology narratives. Conor joins from Cytiva, where he has served as Group Vice President, Marketing. He previously held senior marketing, communications and public affairs roles at GE Healthcare.
Francis Van Parys, Chief Executive Officer of Oxford Nanopore, commented: “As we scale Oxford Nanopore, we are strengthening our leadership team to deepen our focus on customers and accelerate the translation of our differentiated technology into high-performing products, applications and successful customer adoption. David and Conor bring deep experience across product development, commercialisation, customer and market adoption, and will play important roles as we increase our focus on disciplined execution and sustainable growth.”
David Miller said: “Oxford Nanopore has built a truly differentiated technology platform with enormous potential. I’m excited by the opportunity to bring together product, development and applications to turn that innovation into high-performing products and solutions that solve important problems for customers.”
Conor McKechnie said: “Oxford Nanopore has an exceptional technology platform and a significant opportunity across Research, Clinical and BioPharma. I’m looking forward to working with the team to strengthen how we engage with customers and stakeholders, build understanding of the value Oxford Nanopore can deliver, and support the Company’s next phase of growth.”
Both David and Conor will join Oxford Nanopore’s Executive team.
